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1. Introduction 
Imbalance of sodium and potassium in patients on peritoneal dialysis (PD) is not 
uncommon. Sodium is the major extracellular cation; however, its concentrations are mainly 
affected by water balance, as well as sodium balance. Potassium is the major intracellular 
cation, and serum potassium concentrations are very low, compared with its intracellular 
components. Hyponatremia and hypokalemia are associated with severe consequences, 
respectively. I will review development of hyponatremia and hypokalemia in incident PD 
patients, and describe recently emerging evidence related to hyponatremia and 
hypokalemia in PD patients. 
2. Hyponatremia in PD patients 
2.1 Hyponatremia in hospitalized patients 
Hyponatremia is one of the most common electrolyte disorders in hospitalized patients 
(Anderson et al., 1985; Zevallos et al., 2001). Daily incidence and prevalence of 
hyponatremia are approximately 1% and 2.5%, respectively. Two thirds of all hyponatremia 
was hospital-acquired. Normovolemic state (so-called syndrome of inappropriate secretion 
of antidiuretic hormone) is the most commonly seen clinical setting of hyponatremia. 
Hyponatremia, defined as a serum sodium level less than 135 mEq/L, was increased by 20% 
in inpatients with congestive heart failure (Gheorghiade et al., 2007). The fatality rate for 
hyponatremic patients was 60-fold that for patients without documented hyponatremia 
(Anderson et al., 1985). Hyponatremia is an independent predictor of death and myocardial 
infarction in middle-aged and elderly community subjects, respectively (Sajadieh et al., 
2009). Hyponatremic patients with congestive heart failure are associated with a 75% 
increase in 60- to 90-day mortality, compared with normonatremic patients (Gheorghiade et 
al., 2007). Therefore, even mild hyponatremia has a poor prognosis.  
2.2 Pathophysiology of hyponatremia in PD patients 
The prevalence of hyponatremia is approximately 10% in PD patients (Zevallos et al., 2001). 
Because fluid and electrolyte balance in these patients is dependent on nonrenal routes, PD-
related hyponatremia has been suggested to differ pathophysiologically from non-PD-
related hyponatremia. Regulation of a normal serum sodium concentration is dependent on 
the content of sodium and potassium, as well as total body water. Despite a low rate of 
www.intechopen.com
 
Progress in Peritoneal Dialysis 
 
146 
glomerular filtration, the normal kidney can regulate serum sodium concentrations 
independent of solute and water balance. Whereas, in PD patients without residual renal 
function, solute and water balance through peritoneal membrane plays an important role in 
development of hyponatremia (Nolph et al., 1980). Sodium removal by convective transport 
predominates over diffusive transport in patients on PD, thereby requiring augmentation of 
ultrafiltration volume in order to increase sodium removal (Nolph et al., 1980). Due to the 
Gibbs–Donnan effect created by negatively charged proteins in the plasma space, and 
sodium sieving by aquaporins, the typical dialysate sodium concentration is substantially 
lower than the plasma sodium concentration (Rippe & Venturoli, 2008). As a result of this 
sieving, the early part of a PD dwell removes mostly water, and sodium removal occurs 
later in the dwell as the dialysate Na+ concentration decreases, creating a higher gradient for 
diffusive transport of sodium. As a result of its longer dwell times, continuous ambulatory 
PD removes more sodium per ultrafiltration volume than automated PD (Rippe & 
Venturoli, 2008).  
The serum sodium concentration accounts for the balance of three components: mainly 
sodium, potassium, and body water. The basis for hyponatremia is a negative balance for 
sodium plus potassium and/or a positive balance for water. Vasopressin can control water 
permeability in the normally functioning nephron, which leads to electrolyte-free water 
retention. In dialysis patients without residual renal function, the role of vasopressin is 
limited; therefore, solute balance may play a more important role in development of 
hyponatremia (Zanger, 2010). Hypotonic hyponatremia may occur in PD patients, either 
from free water retention or loss of electrolyte, such as sodium or potassium. If 
hyponatremia is accompanied by a quantitatively appropriate gain in weight, a gain of 
electrolyte-free water is the basis for hyponatremia (Cherney et al., 2001). In the absence of 
this weight gain, loss of sodium from the extracellular fluid (ECF) space will lead to 
movement of water into the intracellular fluid (ICF), to restore the equilibrium between 
intra- and extracellular osmolality. Loss of potassium, along with an ECF anion, such as 
chloride or bicarbonate, results in potassium efflux from ICF into ECF, with a shift of 
sodium into the cell for maintenance of electroneutrality (Nguyen & Kurtz, 2004). The net 
effect is loss of sodium from the ECF, with development of hyponatremia (Cherney et al., 
2001). In patients without weight gain, loss of intracellular potassium, with an intracellular 
anion, such as phosphate, will contribute to development of hyponatremia, due to 
movement of water from the ICF into the ECF.  
2.3 De novo hyponatremia in incident PD patients 
In order to control bias on pre-existing hyponatremic conditions, we observed development 
of hyponatremia in incident PD patients, and evaluated factors contributing to its 
development. We conducted a 1-year observational study at a single PD center at Gachon 
University Gil Hospital, South Korea (Lee et al., 2010). Fifty-one incident PD patients were 
enrolled. All patients were ethnic Koreans and older than 18 years. The same protocol used 
in our previous report was used in performance of the peritoneal equilibration test (PET) 
and measurement of dialysis adequacy  at 1 and 13 months after the start of PD (Kim et al., 
2009). Patients with hyponatremia (Na+ < 135 mEq/L) at month 1 were excluded. At month 
13, patients were divided according to their serum sodium levels into hyponatremic (Na+ < 
135 mEq/L) and normonatremic (Na+ ≥ 135 mEq/L) groups.  
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Between the two groups, there were no significant differences in baseline demographics of 
patients beginning PD, including age, sex, height, cause of end-stage renal disease, co-
morbidity, biocompatible fluid, and CAPD versus automated PD. Sixteen percent of 
enrolled patients had de novo hyponatremia 13 months after initiation of PD. Initial serum 
albumin levels of the hyponatremia group were  significantly lower than those of the 
normonatremic group (p = 0.022; Table 1). Median levels of initial serum sodium in the 
hyponatremia group were also slightly lower than those in the normonatremic group; 
however, the difference was not significant. At month 13, the hyponatremia group showed 
no significant difference in serum albumin levels, compared to the normonatremic group. 
   
Parameters 
Month 1 Month 13 
HN NN HN NN 
Serologic parameters     
C-reative protein (mg/dL) 0.15 0.13 0.26 0.13 
Glucose (mg/dL) 173 130 160 120* 
Creatinine (mg/dL) 7.6 7.4 10 7.9 
Albumin (mg/dL) 3.1* 3.7 3.4 3.6 
Cholesterol (mg/dL) 179 171 200 189 
Sodium (mEq/L) 136 140 134* 139 
Potassium (mEq/L) 3.7 4.2 3.8 4.3 
Chloride (mEq/L) 99 101 95* 101 
Total CO2 (mEq/L) 23.4 23.0 22.3 25.9 
Peritoneal function and adequacy tests 
D/P Cr 0.64 0.67 0.75* 0.66 
Maximum dip in DPNa 0.071 0.070 0.091 0.071 
Ultrafiltration capacity (mL) 800 875 700 900 
Weight (kg) 66.5 65.8 66.5 65.5 
nPNA (g/kg/day) 0.81 0.88 0.79 0.88 
Total Kt/Vurea 2.05 2.28 2.19 2.12 
GFR (L/week/1.73m2) 44.8 45.1 53.1* 43.8 
Table 1. Serum levels of the parameters at months 1 and 13 (Lee et al., 2010). Values are 
presented as the median. HN, hyponatremia; NN, normonatremia. D/P Cr, dialysate-to-
plasma creatinine ratio at 4 hours; Maximum dip in DPNa, the difference between the initial 
D/P sodium and the lowest D/P sodium; nPNA, protein equivalent of total nitrogen 
appearance normalized to desirable body weight (generating rate of urea); GFR, Glomerular 
Filtration Rate (average of creatinine clearance and urea clearance). * P-value < 0.05, 
hyponatremia group vs. normonatremic group. 
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No significant differences were observed in serum C-reactive protein, creatinine, cholesterol, 
potassium, or total CO2 between the two groups after 13 months. Several parameters 
changed from month 1 to 13 in PD patients with de novo hyponatremia. Serum albumin 
levels in the hyponatremia group showed a moderate, but not significant increase (p = 
0.058), from 3.10 to 3.45 mg/dL. During the 12-month period, no statistical difference was 
observed in serum glucose, creatinine, cholesterol, potassium, chloride, and total CO2 levels. 
At month 1, the two groups showed no significant differences in peritoneal function and 
adequacy tests. In contrast, at month 13, the D/P Cr was increased to 0.748 in the 
hyponatremia group, compared with 0.662 in the normonatremic group (p = 0.007). The 
glomerular filtration rate measured at month 13 was slightly higher in the hyponatremia 
group (p = 0.021). No other measure of peritoneal function and adequacy differed between the 
two groups. Changes in peritoneal function and adequacy tests in PD patients with de novo 
hyponatremia were observed after 12-month treatments. The D/P Cr showed a significant 
increase (p = 0.036) from 0.644 to 0.748. The glomerular filtration rate tended to be higher at 12 
months (44.8 vs. 53.1 L/week/1.73m2, p = 0.063). A trend toward a decrease in nPNA was seen 
in the hyponatremia group at month 13; however, the difference was not significant. 
We found that the increase in D/P Cr at month 13 was significantly higher in the 
hyponatremia group. The lower fluid removal during a single PD exchange in high 
transporters was not only due to a decrease in the ultrafiltration rate, but also an increase in 
the peritoneal fluid absorption rate (Wang et al., 1998). The decrease in the ultrafiltration 
rate in high transporters is likely due to a rapid decrease in the osmotic gradient resulting 
from increased absorption of glucose from the dialysate. The increased fluid absorption rate 
may be the result of increased peritoneal interstitial hydraulic conductivity, as the peritoneal 
hydrostatic pressure gradient is unlikely to be higher in high transporters. Therefore, 
subjects in the hyponatremia group, who were high transporters, showed lower fluid 
removal, which might lead to free water gain.  
Of particular interest, in this study, despite reduced ultrafiltration capacity, there were no 
changes of body weight in the hyponatremic groups. This finding suggests that 
hyponatremia in incident PD patients can occur due not only to free water gain, but also 
additional causes, including catabolic states or malnutrition. Patients with de novo 
hyponatremia had low levels of initial serum albumin and low levels of nPNA at month 13. 
Serum albumin and nPNA are markers for nutrition and a well-known predictor of 
mortality in PD patients; therefore, these conditions may also contribute to de novo 
hyponatremia (Perez-Flores et al., 2007). Diuretics, which were prescribed to maintain urine 
output, may also affect development of hyponatremia (Sonnenblick et al., 1993). However, 
there was no significant difference between the two groups, although approximately half of 
patients were prescribed diuretics in the current data.  
The majority of the patients still had residual renal function since all the enrolled patients 
were incident cases of peritoneal dialysis. The residual renal function tended to be higher at 
12 months in hyponatremic group. Excessive peritoneal ultrafiltration may, by provoking 
intravascular volume depletion, play a causative role in the decline in residual renal 
function (Konings et al., 2005; Konings et al., 2003). In the present study, it is possible that 
increased D/P Cr and, consequently, lower peritoneal ultrafiltration volume in the 
hyponatremic group might provide a lower risk of intravascular volume depletion and 
higher probability of relative increase of residual renal function. 
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Fig. 1. Pathophysiology of hyponatremia in PD patients 
Our findings showed that the maximum dip in D/PNa did not differ between the two 
groups, while D/P Cr was significantly higher in the hyponatremia group. The sieving 
coefficient for sodium is higher in high transport patients compared, with low transport 
patients (Wang et al., 1997). However, no significant differences were found in our study. 
Discrepancies between studies may be explained by small differences in D/P Cr. The 
average D/P Cr in the hyponatremia and normonatremic groups classified both as high-
average transporters. We observed higher serum glucose levels at month 13 in the 
hyponatremia group, while no change in glucose or uric acid was observed in the 
hyponatremia group from month 1 to 13. Hyperglycemia is associated with a decrease in the 
serum sodium concentration (Roscoe et al., 1975). The expected decrease in the serum 
sodium concentration is 1.35 mEq/L for every 100 mg/dL increase in the blood glucose 
concentration (Roscoe et al., 1975). Therefore, higher serum glucose levels in the 
hyponatremia group were related to the decrease in serum sodium levels.  
2.4 Summary of hyponatremia in PD patients 
The primary cause of hyponatremia is free water gain by the ECF, which is often paralleled 
by an increase in body weight. Intracellular potassium or phosphate loss, 
pseudohyponatremia, and catabolic states are less common causes of hyponatremia 
(Cherney et al., 2001)(Fig. 1). Some studies have demonstrated a relationship between the 
incidence of PD-associated hyponatremia and the catabolic state (Zevallos et al., 2001). They 
reported that tissue catabolism combined with intracellular potassium and phosphate loss 
may lead to hyponatremia in PD patients. Other studies have shown that the main 
determinant of PD sodium loss is the net dialysate ultrafiltration volume (Uribarri et al., 
2004). Treatment with icodextrin-based dialysis solution regimes has also been implicated as 
a risk factor for hyponatremia (Gradden et al., 2001). Increased serum NT-Pro-BNP, a 
predictor of mortality in PD and hemodialysis patients, was found to play a role in 
development of hyponatremia, water balance disturbance, anemia status, and 
hypoalbuminemia in the PD patient group (Adachi & Nishio, 2008).  
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3. Hypokalemia in PD patients 
3.1 Pathophysiology of hypokalemia in PD patients 
A third of PD patients, in whom potassium removal by PD does not explain the occurrence 
of hypokalemia, are frequently hypokalemic (Oreopoulos et al., 1982; Rostand, 1983). Some 
studies have noted that 36% of PD patients have a serum potassium level less than 3.5 
mEq/L at some time during their course and that 20% require potassium supplementation 
(Spital & Sterns, 1985). In addition, hypokalemia is an independent predictor of mortality in 
PD patients (Szeto et al., 2005).  
Potassium homeostasis is maintained by two different balances: the internal balance, 
representing potassium redistribution between intracellular and extracellular 
compartments, and the external balance, representing potassium interchange between the 
organism and the environment (Adrogue & Wesson, 1992). Since fluid and electrolyte 
balance in these patients is dependent on nonrenal routes, PD-related hypokalemia also 
differs pathophysiologically from non-PD-related hypokalemia. Daily consumption of 
potassium exceeds daily elimination with PD; therefore, PD fluid has never contained 
potassium. Enhanced large intestine secretion of potassium in direct proportion to dietary 
potassium intake, which is an additional route of potassium removal, plays an important 
role in maintenance of potassium balance in patients with renal insufficiency (Bastl et al., 
1977; Mathialahan et al., 2005).  
Figure 2 shows the pathophysiology of hypokalemia in PD patients. Serum potassium levels 
in PD patients are associated with nutritional status and severity of coexisting comorbid 
conditions. Hypokalemia in PD patients is due to a shift of potassium into the intracellular 
space, probably due to insulin release during the continuous dwell of the dialysis solution 
containing glucose (Tziviskou et al., 2003). Thus, cellular uptake may play an important role 
in the pathogenesis of hypokalemia. Muscle biopsy studies have shown higher intracellular 
potassium content in PD patients, compared with hemodialysis patients (Lindholm et al., 
1986). Ongoing loss of potassium in dialysate may be another important factor contributing 
to hypokalemia (Szeto et al., 2005). The main driving force for elimination of potassium is 
the diffusive gradient between blood and PD fluid (Brown et al., 1973; Nolph et al., 1980).  
 
 
Fig. 2. Pathophysiology of hypokalemia in PD patients 
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Due to the low concentration of serum potassium, removal of convective fluid, under most 
circumstances, contributes little to potassium removal (Brown et al., 1973; Nolph et al., 
1980). In addition, end stage renal disease patients are instructed to restrict potassium-rich 
foods, such as fruits and vegetables. 
3.2 De novo hypokalemia in incident PD patients 
This study (Jung et al., 2009) was undertaken in order to investigate clinical features and 
factors related to de novo hypokalemia in incident PD patients over the 1-year observational 
period using the same protocol (Lee et al., 2010), which is designed for control of bias on 
pre-existing hypokalemic conditions.  
Eighty-two incident PD patients who were normokalemic at month 1 of PD were enrolled in 
the study. According to the plasma potassium levels at month 13, patients were divided into 
hypokalemic (K+ < 3.5 mEq/L) and normokalemic (3.5 mEq/L ≤ K+ < 5.5 mEq/L) groups. 
Eight patients who showed hyperkalemia at month 13 were excluded. Blood, peritoneal 
function tests, and dialysis adequacy and nutritional status data were taken at months 1 and 
13. The two groups, those with and those without hypokalemia, did not differ significantly 
in age, sex, height, and causes of end-stage renal disease. Medication history of ACE 
inhibitors or angiotensin II receptor blockades and diuretics were not significantly different 
between the two groups. No statistical differences were found between the two groups with 
respect to the Davies comorbidity index, biocompatible fluid, and continuous ambulatory 
PD versus automated PD.  
The incidence of hypokalemia in patients starting PD was 7.3% over the 1-year observation 
period. Whereas the initial serum potassium and albumin levels at month 1 did not differ 
between the two groups, serum albumin level in the hypokalemia group showed a 
significant decrease from 3.1 to 2.9 mg/dL at month 13 (p = 0.014)(Table 2). In contrast, no 
significant differences were observed in serum C-reactive protein, glucose, cholesterol, and 
total CO2 between the two groups at month 13. At month 1, the hypokalemia group showed 
higher serum phosphorus levels and lower cholesterol levels. 
At month 1, the two groups showed no significant differences. nPNA at month 1 was also 
similar between the hypokalemic and normokalemic groups. However, at month 13, the 
nPNA was significantly lower in the hypokalemia group, compared with that in the 
normokalemic group. Other measurements determined for peritoneal function, including 
D/P Cr and daily glucose exposure, did not differ between the two groups.  
In the current study, the incidence of hypokalemia in our PD patients, 7.3% in one year, 
appears relatively low, compared with that of previous reports (Kim et al., 2007; Oreopoulos 
et al., 1982; Rostand, 1983). This is probably because our result was from newly starting PD 
patients. We demonstrated an association between development of hypokalemia in incident 
PD patients and decreases in serum albumin and nPNA. This poor nutritional status can 
lead to de novo hypokalemia. In PD patients, insulin hormone, stimulated by the continuous 
glucose peritoneal dwell, can generate an increase of potassium redistribution into the 
intracellular compartment (Tziviskou et al., 2003). In the present study, the presence of 
diabetes and daily glucose load did not differ between the two groups, suggesting that 
intracellular potassium redistribution may not be the main mechanism of hypokalemia in 
our PD patients. In a cross-sectional study, the serum potassium level of PD patients was 
correlated with ultrafiltration volume (Kim et al., 2007). However, in our longitudinal study, 
no difference in ultrafiltration volume was observed between the two groups at month 13. 
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This finding is consistent with the previous study showing that convective fluid removal 
contributes little to potassium elimination (Brown et al., 1973; Nolph et al., 1980).  
 
 Month 1 Month 13 
 HK NK HK NK 
Serologic parameters     
C-reative protein (mg/dL) 0.53 0.15 0.36 0.18 
Glucose (mg/dL) 158 138 137 127 
Creatinine (mg/dL) 7.6 7.6 8.6 9.4 
Albumin (mg/dL) 3.1 3.7 2.9* 3.7 
Cholesterol (mg/dL) 125* 163 163 174 
Sodium (mEq/L) 136 139 136 139 
Potassium (mEq/L) 4.1 4.2 3.4* 4.5 
Chloride (mEq/L) 101.5 102.0 98.0 101.0 
Total CO2 (mEq/L) 19.5 23.0 23.5 22.1 
Calcium (mg/dL) 8.5 8.5 8.6 8.9 
Phosphorus (mg/dL) 5.6 * 4.2 3.7 4.6 
Peritoneal function and adequacy tests 
D/P Cr 0.68 0.67 0.69 0.67 
Ultrafiltration capacity (mL) 675 850 800 800 
Weight (kg) 63.8 66.0 66.0 63.6 
nPNA (g/kg/day) 0.89 0.91 0.66* 0.91 
Total Kt/Vurea 2.37 2.05 1.94 1.98 
GFR (L/week/1.73m2) 47.0 41.1 48.5 42.6 
Glucose exposure (g/day) 130 120 163 120 
Table 2. Serum parameters at months 1 and 13 (Jung et al., 2009). Values are presented as 
median values. HK, hypokalemia; NK, normokalemia. D/P Cr, dialysate-to-plasma 
creatinine ratio at 4 hours; nPNA, protein equivalent of total nitrogen appearance 
normalized to desirable body weight (generating rate of urea); GFR, Glomerular Filtration 
Rate (calculated as the mean of the values for creatinine and urea clearances) * P-value < 
0.05, hypokalemia group vs. normokalemic group. 
3.3 Summary of hypokalemia in PD patients  
Ten to 58% of patients on PD are known to develop hypokalemia (K+ < 3.5 mEq⁄L)(Khan et 
al., 1996; Rostand, 1983; Spital & Sterns, 1985). The wide range of prevalence of hypokalemia 
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may depend on dietary consumption of potassium according to the study population or 
ethnicity. Compared with Caucasians, Asians and African Americans tend to have lower 
daily potassium intake (Gao et al., 2009; Kant et al., 2007; Szeto et al., 2005). In a group of 266 
Chinese PD patients, prevalence was reported as 20.3%, and hypokalemia was found to be 
an independent predictor of mortality, although causes of death in the hypokalemic group 
did not differ from those in the normokalemic group (Szeto et al., 2005). In other Asian PD 
patients, hypokalemia can be considered a nutrition marker, such as serum albumin or 
normalized protein nitrogen appearance (nPNA) (Chuang et al., 2009; Szeto et al., 2005). 
Therefore, hypokalemia is associated with poor clinical outcomes, including malnutrition 
and death. New evidence points to a link between hypokalemia and the risk of peritonitis. 
Hypokalemia and malnutrition may increase the incidence of Enterobacteriaceae peritonitis, 
which is caused by impairment of gut mobility, small bowel overgrowth with colonic flora, 
and bacterial translocation across the bowel wall (Berg, 1992; Casafont et al., 1997; Chuang et 
al., 2009). Particularly in diabetic patients, hypokalemia may be associated with impaired 
bowel motility and bacterial overgrowth (Shu et al., 2009). A study of 140 Asian PD patients 
found a higher incidence of peritonitis in hypokalemic patients, compared with 
normokalemic patients, and the incidence of peritonitis due to Enterobacteriacea was found 
to be higher in the hypokalemic group, compared with the normokalemic group (Chuang et 
al., 2009). Both hypokalemia and markers of malnutrition may be independent risk factors 
for development of peritonitis. Further studies are warranted for determination of whether 
correction of hypokalamia can result in reduced risk of peritonitis. 
4. Conclusion  
Hyponatremia occurs frequently in patients undergoing PD. Therefore, one must 
understand its pathophysiology, since the therapeutic strategy differs from that of non-PD-
related hyponatremia. Incidence of PD-associated hyponatremia is mainly related to fluid 
overload. Tissue catabolism combined with intracellular potassium and phosphate loss may 
also lead to hyponatremia. Sodium loss through peritoneal membrane is associated with the 
dialysate ultrafiltration volume, although that may be of little effect. Hypokalemia also 
develops commonly in PD patients. Serum potassium levels in PD patients may be 
influenced by nutritional status and severity of coexisting comorbid conditions. 
Development of hypokalemia can be due to a shift of potassium into the intracellular space, 
which is related to insulin release during the continuous dwell of the dialysis solution 
containing glucose. Ongoing loss of potassium in dialysate may be another important factor 
contributing to hypokalemia; however, potassium loss may not be related to ultrafiltration 
volume. Recently, hypokalemia has been considered as a risk factor for peritonitis in PD 
patients. This common electrolyte imbalance in PD patients is associated with severe 
consequences, morbidity, and mortality. Therefore, hyponatremia and hypokalemia should 
be monitored more carefully in these patients. 
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